

**Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab)  
Recombinant Antibody  
Catalog # APR10202****Specification****Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">O9NZQ7</a>
Reactivity	Rat, Human, Mouse, Rabbit, Dog
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	150 KDa

**Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) - Additional Information****Target/Specificity**  
B7-H1 / PD-L1 / CD274**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) - Protein Information****Name** CD274 ([HGNC:17635](#))**Function**  
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:<a href="http://www.uniprot.org/citations/11015443" target="\_blank">11015443</a>, PubMed:<a href="http://www.uniprot.org/citations/28813410" target="\_blank">28813410</a>, PubMed:<a href="http://www.uniprot.org/citations/28813417" target="\_blank">28813417</a>, PubMed:<a href="http://www.uniprot.org/citations/31399419" target="\_blank">31399419</a>). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:<a href="http://www.uniprot.org/citations/11015443" target="\_blank">11015443</a>, PubMed:<a href="http://www.uniprot.org/citations/28813410" target="\_blank">28813410</a>, PubMed:<a href="http://www.uniprot.org/citations/28813417" target="\_blank">28813417</a>, PubMed:<a href="http://www.uniprot.org/citations/36727298" target="\_blank">36727298</a>). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:<a

href="http://www.uniprot.org/citations/10581077" target="\_blank">10581077</a>). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:<a href="http://www.uniprot.org/citations/32929201" target="\_blank">32929201</a>).

#### Cellular Location

Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein. Nucleus. Note=Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation (PubMed:28813417). Translocates to the nucleus in response to hypoxia via its interaction with phosphorylated STAT3 (PubMed:32929201). [Isoform 2]: Endomembrane system; Single-pass type I membrane protein

#### Tissue Location


Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.

### Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


### Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) - Images




Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) is more than 98.22%, determined by SEC-HPLC.



Immobilized human PD L1 FC at 2 µg/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (avelumab) EC<sub>50</sub>=0.03725 µg/mL



Avelumab inhibited the tumor growth of MC38 on hLAG3 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 32.6% at 1 mpk at D28.